echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Nutrition News > Chemoimmunotherapy significantly improves the survival rate of patients with high-risk neuroblastoma

    Chemoimmunotherapy significantly improves the survival rate of patients with high-risk neuroblastoma

    • Last Update: 2021-12-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Neuroblastoma is a cancer of immature nerve cells in the sympathetic nervous system


    The results of the St.


    "I have been treating high-risk neuroblastoma for 30 years, and I have never seen such results in high-risk patients," said Wayne Furman, MD, the first author and corresponding author of the Department of Oncology


    Forman said that if this finding is confirmed in a larger, multicenter clinical trial, the immunochemotherapy detailed in this study may become the standard treatment for patients with high-risk diseases


    An anti-gd2 monoclonal antibody

    Hu14.


    Hu14.


    The phase II study included hu14.


    What is the key?

    Dinutuximab is the first anti-gd2 monoclonal antibody approved by the US Food and Drug Administration for the treatment of high-risk neuroblastoma


    The dose of hu14.


    Forman said: “Because dinuciimab cannot be given at the same dose, an unanswered question is whether the results of the patients in this study are so good because hu14.


    Hu14.


    Journal Reference :

    1. Wayne L.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.